Navigation Links
AMDL Reports Going Concern Qualification
Date:5/9/2008

TUSTIN, Calif., May 9 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), an international vertically integrated specialty pharmaceutical company with operations in China through its wholly owned subsidiary, Jade Pharmaceutical Inc., today announced that its consolidated financial statements for the year ended December 31, 2007, which were included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 14, 2008, contained a 'going concern' qualification from its independent registered public accounting firm KMJ Corbin & Company LLP. This announcement is in compliance with the AMEX Company Guide Rule 610(b) requiring a public announcement of the receipt of an audit opinion that contains a going concern qualification. This announcement does not reflect any change or amendment to the consolidated financial statements as filed. Further information regarding the going concern qualification is contained in AMDL's Annual Report on Form 10-K for the year ended December 31, 2007.

Mr. Gary Dreher, CEO, stated, "Significant improvements in AMDL's China operations combined with other recently announced events provide a financial platform for the Company to improve its sales and earning profile during the second half of FY2008 and beyond, giving us greater confidence in AMDL's financial performance in 2008. Accordingly, we anticipate AMDL will be to in a position to have our auditors remove the 'going concern' qualification after the end of the current fiscal year." The business improvement and opportunities referenced above include:

* FY2007 Sales of $15 million and, Gross Profits of $8.1 million;

* In-licensed Human Papilloma Virus ("HPV") Diagnostic Test;

* Signed LOI for the Purchase a China Based Pharmaceutical Distribution

Company;

* Signed an MOU for 200 Store Distribution Arrangements for theGoodnak

Product Line;

About Jade Pharmaceutical: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AutoImmune Inc. Reports 2008 First Quarter Financial Results
2. Bioniche Reports Fiscal 2008 Third Quarter
3. DRAXIS Health Reports Results for the First Quarter of 2008
4. Par Pharmaceutical Reports First Quarter 2008 Results
5. Air Methods Reports 1Q2008 Results and 2Q2008 Update
6. Genoptix Reports Strong Financial Results for First Quarter 2008
7. IDM Pharma Reports First Quarter Financial Results
8. General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results
9. Orchid Cellmark Reports First Quarter 2008 Financial Results
10. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
11. Micromet, Inc. Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
Breaking Medicine Technology: